FDA Scientists Reject 7 Peptides for Compounding as RFK Jr. Pushes Deregulation
Updated
Updated · NBC News · Jun 30
FDA Scientists Reject 7 Peptides for Compounding as RFK Jr. Pushes Deregulation
2 articles · Updated · NBC News · Jun 30
Summary
Briefing documents released before the July 23-24 advisory meeting say all seven peptides under review lack enough evidence to be added to the FDA list for pharmacy compounding, and scientists could not rule out safety risks.
Human data were especially thin: FDA reviewers found no human studies for TB-500, KPV or MOTS-c, and said evidence was also insufficient for BPC-157, semax, epitalon and emideltide.
The findings cut against Health Secretary Robert F. Kennedy Jr., who in April moved 12 peptides into Category 1 and has argued wider compounding access could pull buyers away from an online gray market.
The committee's recommendation will matter because the FDA usually follows advisory panels, though some newly named members work at wellness centers that promote or sell peptides, raising conflict concerns.